Enliven Therapeutics (ELVN) Preferred Stock Liabilities (2019)

Enliven Therapeutics has disclosed Preferred Stock Liabilities across 1 years of filings, most recently posting $77.8 million for Q4 2019.

• Preferred Stock Liabilities for Q4 2019 came in at $77.8 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $77.8 million (changed N/A YoY), and the FY2019 annual result was $77.8 million, changed N/A from the prior year.
• Preferred Stock Liabilities came in at $77.8 million for Q4 2019 at Enliven Therapeutics, up from $45.6 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $77.8 million in Q4 2019 to a low of $30.7 million in Q2 2019.